Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026
Pharma-Bio Serv grew revenue and turned a year-to-date profit, though the latest quarter still showed a small net loss.
Rhea-AI Summary
Pharma-Bio Serv (PBSV) reported results for the three and nine months ended July 31, 2026, showing higher revenue and improved profitability versus the prior-year periods.
Revenue was approximately $2.3 million for the quarter and $7.3 million for the nine months, up about $0.4 million and $0.5 million, respectively, from a year earlier. The company posted a quarterly net loss of $14 thousand, but nine‑month net income of about $252 thousand, representing improvements of roughly $190 thousand and $352 thousand compared with the corresponding 2025 periods. Management attributes the better performance to a focus on markets where its regulatory and compliance expertise provides a competitive edge and to operating efficiencies.
Positive
- Quarter revenue approximately $2.3 million, up about $0.4 million year over year
- Nine-month revenue approximately $7.3 million, up about $0.5 million year over year
- Quarterly net result improved by about $190 thousand versus prior year period
- Nine-month net income about $252 thousand, a $352 thousand improvement year over year
Negative
- Quarterly net loss of about $14 thousand despite revenue growth
AI-generated analysis. How Rhea-AI works. Not financial advice.
DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm today announced that revenues for the three and nine months ended July 31, 2026 were approximately
For the three and nine months ended July 31, 2026, the Company reported a net loss of
"Our Q3 results demonstrate the strength of our client relationships and the value of our specialized regulatory and compliance capabilities. By sharpening our focus on markets where our expertise creates a distinct competitive advantage and continuing to drive operating efficiencies, we meaningfully improved our financial performance. We remain confident in our ability to build on this progress and carry that momentum through the final quarter of the year," said Victor Sanchez, Chief Executive Officer.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries to Puerto Rico, United States, Europe and Brazil markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787-278-2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What services does Pharma-Bio Serv provide?
Pharma-Bio Serv provides compliance, project management and technology transfer support consulting services. Its core business is FDA and international agencies regulatory compliance consulting–related services for clients in the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries.
In which markets does Pharma-Bio Serv operate?
The company serves clients in Puerto Rico, the United States, Europe and Brazil through a global team of engineering and life science professionals, quality assurance managers and directors.
How does management describe the drivers of recent financial improvements?
The company attributes its improved financial performance to a sharper focus on markets where its regulatory and compliance expertise provides a distinct competitive advantage and to ongoing efforts to drive operating efficiencies. Management also highlights the strength of client relationships and specialized capabilities.